Table 1 Clinical trials of protein degrader presented at ASH 2023
Compound | Modality | Target | Indication | Clinical Stage | Clinical Trial ID | Reference |
|---|---|---|---|---|---|---|
BGB-16673 | PRTOAC | BTK | R/R B-cell malignancies | Phase 1 | NCT05006716 | [1] |
NX-5948 | PRTOAC | BTK | R/R B-cell malignancies | Phase 1a/b | NCT05131022 | [2] |
NX-2127 | PRTOAC | BTK/Ikaros /Aiolos | R/R B-cell malignancies | Phase 1a/b | NCT04830137 | [3] |
KT-333 | PRTOAC | STAT3 | R/R lymphoma, LGL-L, and ST | Phase 1a/b | NCT05225584 | [4] |